- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Opinion
Video
Advancing to Systemic Treatment in an 8-Year-Old Girl With Atopic Dermatitis
Author(s):
The panelist discusses how an 8-year-old girl with moderate to severe atopic dermatitis requires a comprehensive treatment approach focusing on dupilumab as a potential systemic therapy. Treatment goals include reducing inflammation, improving quality of life, and providing age-appropriate, empathetic care while addressing patient and caregiver concerns about efficacy and safety.
Video Player is loading.
Video content above is provided by the following:
- Please share your impressions of the case. What aspects of the case are most relevant for treatment consideration?
- What are your treatment goals for this patient?
- Describe your approach to pharmacologic treatment for this patient. Would her history and presentation make her a candidate for systemic therapy?
- How do you approach the conversation with pediatric patients and their caregivers when initiating a systemic, injectable treatment for atopic dermatitis?
- What should this patient expect in terms of efficacy and safety with dupilumab? How soon can she expect initial symptom relief?
- How would you address potential patient/caregiver concerns such as fear of injections or adverse effects and long-term safety with dupilumab?
Related Videos
Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies
Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children
Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists
Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability
Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis
Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma
Differentiating Between JAK Inhibitors in Clinical Practice
IL-17 Inhibitor Treatment Impact on Quality of Life in Psoriasis and Psoriatic Arthritis
Clinical Attributes of IL-17 Inhibitors in Psoriasis
Laboratory Monitoring with Oral JAK Inhibitors
Related Content
